

ORIGINAL RESEARCH

Genetic variants linked to T2DM risk in Kurdish populations

This article was published in the following Dove Press journal: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Shadi Golsheh Fatemeh Keshavarzi²

¹Department of Biology, Kurdistan Science and Research Branch, Islamic Azad University, Sanandaj, Iran; ²Department of Biology, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran

Background: The polymorphisms of the C–C chemokine ceptor type CCR5) and the insulin receptor substrate I (IRSI) have been studied candiles for the develop type 2 diabetes mellitus (T2DM). CCR5 is a chinokine recept and re polymorphisms in the promoter region of this receptor are being udied a andidates of the susceptibility to this gene have been reported, which controlled to the activity to evelop T2DM. The aim of the current study was at a least of the current study was at a least of the current study was at a least of the current study. current study was to determine real onship between CCR5 (59029A/G) and IRST (rs10498210) polymorphisms with T2DM in San dajian patients.

Methods: Genomic DNA was soluted from 200 althy individuals and 220 Kurdish T2DM patients by salt extraction method and the polymorphisms were examined by restriction fragment length polymorphen (RFLP) method and then the results were analyzed using Chisquare test.

of AA ype in 220 Kurdish patients for both genes CCR5 Results: The f R [95% CI]=2.62, P=0.02) were significantly more than gnificant association between AG or GG genotypes in with T2DM. usion The presence of AA homozygote alleles in both loci of IRS1 (rs10498210) and $\sqrt{5}$ (5902 $\sqrt{3}$) gen increased the risk of T2DM.

: 1RS1 (1. 0498210), CCR5 (59029A/G), type 2 diabetes, Kurdish patients



troduction

Dia etes or diabetes mellitus is referred to as a heterogeneous group of metabolic disorders characterized by chronic hyperglycemia and carbohydrate, fat and protein metabolism disorders that result from a defect in the secretion of insulin, or impairment in its function, or both. Types of diabetes mellitus include type 1, type 2 diabetes and other kind of diabetes, but the two most common types of diabetes mellitus are type 1 and type 2, which are different in several aspects.^{1,2} Type 1 diabetes has been identified with autoimmune destruction of pancreatic beta cells (insulin secreting cells) and accounts for about 5% of all diabetic people, while type 2 diabetes mellitus (T2DM) is a predominant disorder characterized by insulin resistance or a relative decline in insulin production, and accounts for about 90% of all types of diabetes mellitus.³ Important factors that predispose a person to T2DM are multifactorial, including genetic factors and environments. However, its inheritance has certainly not been proven, but it is believed that first-degree relatives of diabetic patients have a higher chance to develop the disease. In this regard, recognizing gen polymorphisms of this disease seems to be necessary.4

Correspondence: Fatemeh Keshavarzi Sanandai Branch, Islamic Azad University, Pasdaran Avenue, Sanandaj, Iran Tel +98 918 370 4918 Fax +98 873 328 8677 Email fkeshavarzi@iausdj.ac.ir

Golsheh and Keshavarzi Dovepress

Multiple genes have been studied in the pathogenesis of T2DM. One of these genes associated with T2DM is the *IRS1* gene (accession number. 147545).^{5–8} Another gene associated with T2DM is the *CCR5* gene (accession number. 601373).^{9–11}

Insulin initiates a wide range of growth and metabolic effects by binding to its receptor and activating the property of tyrosine kinase. These events cause phosphorylation of tyrosine kinase residues at the level of anchored proteins, which include insulin receptor substrate proteins (IRS). 12 The phosphorylated IRS proteins are used as multi-position anchored proteins for different molecules that have homologous domains (SH2) or Src. The activity of these second SH proteins triggers the signaling cascade and results in the activity of several downstream filters that ultimately transmits the insulin message to the cellular vector pathways, thereby regulating cell differentiation, growth, survival and metabolism. In different studies, the frequency of IRS1 polymorphisms in type 2 diabetic patients was more than control group. 13-15 The IRS1 is a cytoplasmic substrate for insulin and also is a receptor for IGF-1, which plays a vital role in signaling. In recent studies, various roles in IRS1 have been discovered, especially in patients with non-insulin diabetes mellitus. The IRS1 gene polymorphisms were identified 1993.16,17

Chemokines are a large family of low molecular weight secretion proteins that play fundamental roles in gical and pathophysiological processes such angio inflammation, atherosclerosis and autoinnune dergic or infectious diseases. 18,19 Their initial action is to relate the migration of leukocytes at the concentration gradient, but they also play a role in the active on of the centeroducing and secreting inflammatory metators. These chemokines do their function by connecting to fir G-protein receptors. 19 Excessive nutrition that have gh level of glucose and fatty ne atic islets and insulinacids can put ress n the sensitive tisses such a fet and liver and muscle, leading to the production elease of topical cytokines and inflammamong these inflammatory chemokines, tory chemokines. MCP-1, MIP-1 α , MIP-1 β , RANTES (Regulated upon Activation, Normal T-cell Expressed, and Secreted) and MCP-2 are mentioned. These chemokines interact with their receptors, triggering monocytes, as well as increasing the number of macrophages in the inflammation position. Chemokine receptors that can be mentioned include CCR2 (CC chemokine receptor type 2), chemokine receptor MCP-1, and also chemokine receptors CCR5, MIP-1a, MIP-1B, RANTES and MCP-2.²¹

The *CCR5* gene is located at 3q21.3 position on the chromosome. The *CCR5* (59029A/G) polymorphism has been reported in the promoter region of the *CCR5* receptor gene.²² Studies indicated that the *CCR5* (59029A/-) genotype results in increased expression of this receptor by peripheral blood mononuclear cells of individuals with this genotype, and therefore it is probably the genotype regulating the expression of the *CCR5* gene.^{9,20}

In this regard, the relationship between the *IRS1* (rs10498210) polymorphisms and *CCR5* (59029A/G) and the risk of T2DM have not been clearly and precisely indicated. Therefore, this study was conjucted with the aim of investigating this relationship.

Methods

Ethical statement

The study was chically approved of the regional Ethics Committee of Sah adaj Branch Islamic Azad University, and the study was conjected in accordance with the provisions of the Declaration of Helsinki.

Saroles

This re case-control study. During this study, the sheral blood samples of 220 T2DM patients (fasting od ga cose higher than 150 mg/dL in two times) and non-200 diabetic subjects as control (fasting blood glucose ss than 100 mg/dL in two times and gender- and ethnicmatched with the patients). Patients were selected randomly among individuals who referred to the Kurdistan Diabetes Centers in Kurdistan of Iran. Patients were selected in such a way that their diabetes was controlled (measured by HbAlc by the diabetes center). Inclusion criteria were diagnosed according to the American Diabetes Association diagnostic criteria (the blood glucose level of >250 mg/dL or severe hyperglycemia). Written consent was received from the individuals and they were informed that sampling was for research purposes only.

DNA extraction

Extraction of DNA from the blood samples was performed by salt extraction method and DNA extraction was determined on agarose gel 1%. The isolated DNA was placed in separate microtubes and stored at -20° C until PCR was performed.

Molecular analysis

Determination of genotype was carried out by PCR-RFLP method and the primers (Table 1) were used for replication

Dovepress Golsheh and Keshavarzi

Table I The sequences of primers used in the study for IRS1 (rs10498210) and CCR5 (59029A/G)

	IRS1(rs10498210)	CCR5 (59029A/G)
Forward	5'-ACAGCCAAAAGGTAAAGCGT-3'	5'-CCCGTGAGCCCATAGTTAAAACTC-3'
Reverse	5'-CCCTTCTCAAAGTACAGCATGT-3'	5'-TCACAGGGCTTTTCAACAGTAAGG-3'
Product size	bp371	bp258

Abbreviation: T2DM, type 2 diabetes mellitus.

of pieces. For the *CCR5* (59029A/G) polymorphism, the primers were taken from other articles but for *IRS1* (rs10498210) polymorphism was designed.

PCR was performed in final volume of 20 µl using Sinagene PCR kit. The PCR cycles of the desired gene are presented in Table 2 separately. To ensure the correct replication of the desired piece, the PCR products were loaded on agarose gel 1.8%. and its quality was determined.

In order to cut the desired region in the CCR5 gene, the SduI enzyme was selected, which is detected as GGGCAC, and consequently, in the presence of the allele G in polymorphic position, enzyme cut the piece and in the presence of the allele A, the piece does not cut. The piece produced by PCR for the CCR5 gene is a 258 bp base pair piece, and if the piece is cut, two pieces of 131 and 127 bases are created. To cut the desired region in the *IRS1* gene, the MaeII enzyr selected, which is detected as ACGT. The PCR-prolift ated piece is 371 bp. In the presence of the allele G in the p morphic position, the enzyme has cut position, which result in two pieces of 229 and 142 bp, and the presence of the allele A at the polymorphic position the piece is not broken, and totally one piece wifemain. The the digested products were loaded on 3% gards gel and the genotypes were determined. Achieval frequencies ignificance between type 2 and control surects were statistically analyzed using SPSS v20 and at significant software popgene 2 and level (p < 0.05)

Results

This case-control study was performed on 420 unrelated individuals, including 220 patients with type 2 diabetic and 200 healthy controls. The allele equence of genotypes for all two SNPs were shown Table 3. In the population studied, the frequency A, A G d GG g otypes of the CCR5 gene were 12 (54.54), 84 8.1 and 16 (7.27), respectively, among the patrats and 81 (40.5), 70 (35) and 49 (24.5), respectively the copy subjects. Also, in the IRS1 gene was as follows: mong the 220 patients, the frequency of A AG and OG was 150 (68.18), 52 (23.63) and 20 (9.09), respectively, and also, among the 200 control ojects, the frequency of GG, AG and AA were 176 (88), 20 10) and 4 (2 respectively. In patients, the allelic frequency AA in bot genes CCR5 (OR (95% CI)=1.9 P=0.02) and 75% CI)=2.62 P=0.02) were significantly more on controls. There was no significant association between AG or GG genotypes in with T2DM (Table 3).

Figure 1 shows the image of the agarose gel 3% for *CCR5* (59029A/G) polymorphism and also shows how to determine its genotype in ladder and size pieces as described above.

Figure 2 shows the image of the agarose gel 3% for *IRS1* (rs10498210) polymorphism and also shows how to determine its genotype in ladder and size pieces as described in "Molecular analysis" section.

In this study, Hardy Weinberg equilibrium and heterozygosity were also studied for populations. The Hardy Weinberg

Table 2 | Sliferation conditions

Genes	Initial denaturation	Denaturation	Annealing	Extension	Final extension	
Cycling condition						
CCR5	94°C 4 Min	94°C 30 Sec	60°C 60 Sec	72°C 60 Sec	°72°C 5 min	
Repeated for 34 Cycles						
IRSI	94°C 4 Min	94°C 30 Sec	60°C 60 Sec	72°C 60 Sec	72°C 5 min	
Repeated for 34 Cycles			•		•	

Golsheh and Keshavarzi Dovepress

Table 3 Distribution of alleles and genotypes of CCR5 (59029A/G) and IRS1 (rs10498210) genes among T2DM patients and healthy controls

Genes variant		Patient n=220 (%)	Control n=200 (%)	Odds ratio (95% CI)	p-value	*Pcorr
CCR5 (59029A/G)	AA	120 (54.54)	81 (40.5)	1.90 (1.04–3.39)	0.02	0.03
	AG	84 (38.18)	70 (35)			
	GG	16 (7.27)	49 (24.5)			
	Alleles					
	G	116 (26.36)	192 (96)			
	Α	324 (73.63)	208 (104)			
IRS1 (rs10498210)	AA	150 (68.18)	176 (88)	2.62 (1.61–4.89)	0.001	0.003
	AG	52 (23.63)	20 (10)			
	GG	20 (9.09)	4 (2)			
	Alleles					
	G	92 (20.90)	28 (7)	0.31 (0.13–0.61)	201	0.0003
	Α	352 (80)	372 (93)			

Abbreviation: T2DM, type 2 diabetes mellitus.



Figure I Genotype detection (59029A/G) CCR5.




Figure 2 Genotype detection (rs10498210) IRS1.

equilibrium points to the fact that the genetic and genotype frequency is constant from generation to generation. The probability level in both type 2 diabetic and control subjects was greater than 0.05 for *IRS1* and *CCR5* genes, indicating a Hardy Weinberg equilibrium in these populations (Table 3).

Heterozygosity for a gene position is defined as a frequency of heterozygote people for that position relative to the total population. For a gene position, if the heterozygosity is greater than 0.1, it is polymorphic and if it is more than 0.7, it is extremely polymorphic. Based on the results of this study, it was found that the difference between observed and expected heterozygosity for both studied polymorphisms was less than 0.1, so that the gene positions in this study are not polymorphic. In the next step, the mean of patient's clinical data which were collected from their files in Diabetes Center of Kurdistan was analyzed. The results of clinical data analysis are presented in Tables 4 and 5.

Discussion

This case-control study was performed on patients and healthy control from Iranian Kurdistan. The frequencies of genotypes and alleles for all two SNPs are shown in Table 3. Results show that among patients and control subjects the Dovepress Golsheh and Keshavarzi

Table 4 Comparison of type 2 diabetic patients' clinical data among different genotypes of polymorphism *IRS1* (rs10498210)

Clinical data	AG-GG	AA-GG	AA-AG
Weight	0.196	0.107	0.536
Systolic blood pressure	0.995	0.633	0.700
Diastolic blood pressure	0.154	0.027	0.203
Total cholesterol	0.322	0.057	0.447
Triglyceride	0.532	0.443	0.958
Cholesterol HDL	0.428	0.000	0.000
Cholesterol LDL	0.277	0.098	0.288
Fasting blood glucose	0.924	0.029	0.016
HBAIC	0.428	0.453	0.768

Table 5 Comparison of type 2 diabetic patients' clinical data among different genotypes of polymorphism *CCR5* (59029A/G)

Clinical data	AG-GG	AA-GG	AA-AG
Weight	0.664	0.075	0.156
Systolic blood pressure	0.000	0.211	0.086
Diastolic blood pressure	0.540	0.867	0.079
Total cholesterol	0.263	0.000	0.000
Triglyceride	0.061	0.771	0.219
Cholesterol HDL	0.102	0.077	0.536
Cholesterol LDL	0.430	0.000	0.000
Fasting blood glucose	0.000	0.000	0.220
HBAIC	0.798	0.456	0.4

allelic frequency AA, AG and GG genot es of e CCI gene were 120 (54.54), 84 (38.18) at 16 (72) (40.5), 70 (35) and 49 (24.5), respectively. o, in the IRS1 220 patie gene it was as follows: among the allelic frequency of AG, AG and was 50 (68.18), 22 (23.63) and 20 (9.09), respective, and also, and ng the 200 control subjects, the frequer of GG AG and AA was 176 (88), 20 (10) and 4 (responsely. The frequency of AA genotype in retients with geods CCR5 (OR (95% CI) 2) and IRS1 (2 5% CI)=2.62 P=0.02) was =1.9 P=0then controls. There was no significant significantly mo association ween AG or GG genotypes with T2DM weight, systolic blood pressure, diastolic (Table 3). An blood pressure, otal cholesterol, triglyceride, cholesterol HDL, cholesterol LDL, fasting blood glucose and HBA1C were significantly higher in the patients' group when compared to the control group (Tables 4 and 5).

McDermott et al., who found for the first time the A/G polymorphism in the 59029 base pair in the promoter region of this gene, reported that both alleles of this polymorphism are common in societies, and the allelic frequency of 59029A, depending on the ethnic population,

varies between 43% and 68%. Differences in the frequency of allelic A in different communities can be due to genetic differences between populations.^{22,23}

According to the results, it is possible that the *CCR5* genotype (AA 59029) plays an important role in the pathogenesis of T2DM. Studies indicated that the *CCR5* (59029A/-) genotype results in increased expression of *CCR5* by peripheral blood mononuclear cells of individuals with this genotype. In a study by Dytfeld et al., the expression of *CCR5* receptor expression was measured on the peripheral blood mononuclear cells of type 2 liabetics, and it was determined that the expression *CCR5* receptor on the cell surface in type 2 diabetic patients is also increasing, and high expression of this recept can be ansidered as an indicator of atherosclerosis in Labetic people.

Given the evidence of 2DM which was recently provided and type 2 diables introduced as an inflammatory disease, include the expectational high expression of this receptor (CCR), on the level of single-cellular cells of the black creases in anymatory responses and increases the sk of T2DM. However, in order to confirm with certainty the existence of such a connection, further studies in a vider population are needed.

lin signaling and the negative effect of rs10498210 polymorphism on the performance of this protein, it can be expected that this polymorphism is present in the etiology of T2DM. Recent studies have indicated that *IRS1* plays an important role in regulating insulin secretion in beta cells of the pancreas. It has been shown that glucosestimulated insulin secretion may be triggered by the autocrine activation of insulin signaling pathway, including insulin receptor phosphorylation, tyrosine phosphorylation in *IRS1* and the activation of *P13-Kinase*.

Putting together these data leads to the hypothesis that a single molecular impairment in the pathway of insulin signaling, including an incomplete interaction between *P13-Kinase* and *IRS1*, may lead to insulin resistance, as well as insulin secretion defect.

So far, there has been a weak link between this polymorphism and T2DM, especially in obese people, but few studies have reported the association between this polymorphism and diabetes. In general, a variety of allele A in *IRS1* frequencies have been reported in many studies, and controversial reports have revealed the association of this polymorphism with type 2 diabetes. Finally, according to the results of this study, it can be concluded that the probability of positive effect of allele A on studied

Golsheh and Keshavarzi **Dove**press

polymorphisms *IRS1* (rs10498210) and *CCR5* (59029A/G) increase the risk of T2DM. Also, clinical data from diabetic patients suggest that the allele A from both studied polymorphisms plays a positive role in increasing the risk of cardiovascular disease in type 2 diabetic patients. However, to be sure about the impact of these polymorphisms on T2DM, it is necessary to study a larger population. It is also possible to compare the clinical data of patients with healthy subjects and examine the effect of these two polymorphisms on the clinical data of these two groups and more effectively to study the role of these polymorphisms in increasing the risk of disease cardiovascular disease. The two studied genes in current study are associated with insulin resistance based on two different mechanisms. IRS1 plays a role in the insulin signaling pathway in its target tissues and CCR5 plays a role in the inflammation pathway in fatty tissues and beta cells in the pancreas. By simultaneous examination of these two genes and the effect of their different variants together, in type 2 diabetic patients, greater recognition of the importance of each of these pathways in the pathogenesis of T2DM can be obtained.

Conclusion

The presence of AA homozygote alleles in both loci of *IRS*. (rs10498210) and CCR5 (59029A/G) genes incre of T2DM. There was no significant association etween G or GG genotypes in with T2DM.

Acknowledgment

nk the volu The authors would like to eers who contributed samples for this udy.

Disclosure

port no conflict The authors interest in this work.

Reference

- 1. Bhattacharya S, Dey Roy SS. Molecular mechanism of insulin resistance. J Biosci. 2007;32(2):405-413.
- 2. Meshkani R, Taghikhani M, Mosapour A, et al. 1484insG polymorphism of the PTPN1 gene is associated with insulin resistance in an Iranian population. Arch Med Res. 2007;38(5):556–562. doi:10.1016/j. arcmed.2007.01.010
- 3. Meshkani R, Taghikhani M, Al-Kateb H, et al. Polymorphisms within the protein tyrosine phosphatase 1B (PTPN1) gene promoter: functional characterization and association with type 2 diabetes and related metabolic traits. Clin Chem. 2007;53(9):1585-1592. doi:10.1373/ clinchem.2007.088146

4. Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650-1659. doi:10.2337/dc13-2105

- 5. Brunetti A, Chiefari E, Foti D. Recent advances in the molecular genetics of type 2 diabetes mellitus. World J Diabetes. 2014;5 (2):128–140. doi:10.4239/wjd.v5.i2.128
- 6. Brender JR, Krishnamoorthy J, Messina GM, et al. Zinc stabilization of prefibrillar oligomers of human islet amyloid polypeptide. Chem Commun (Camb). 2013;49:3339-3341. doi:10.1039/c3cc40383a
- 7. Alharbi KK, Khan IA, Munshi A, Alharbi FK, Al-Sheikh Y, Alnbaheen MS. Association of the genetic variants of insulin receptor substrate 1 (IRS1) with type 2 diabetes mellitus in a Saudi population. Endocrine. 2014;47(2):472-477. doi:10.1007/s12020-014-0177-2
- 8. Alharbi KK, Khan IA, Abotalib Z, Al-Hake M. Insulin receptor substrate-1 (IRS1) Gly927Arg: correlation with go mellitus in Saudi women. Biomed es Int. 2014, 14:146-495. doi:10.1155/2014/146495
- 9. Mokubo A, Tanaka Y, Nakaji a K, e. Chemota c cvtokine 9029A/G) is moter polyni receptor 5 (CCR5) gene hism associated with diabetic phropathy 2 diabetes: a 10-year lo ituding at atients with type Japan study. Diabetes Res Clin Pract. alabres.20° 2006;73(1):89-94. 1:10.1 12.006
- uso C, Granddi MP et al. Ccr5 receptor. Ann 10. Balistreri CR, 1100(1):162-N Y Acad Sci
- 100(1):162 oi:10.1196/annals.1395.014 S, Bakker S, et al. CCR5Δ32 genotype is 11. Muntinghe L, Gro associated with outcond in type 2 diabetes mellitus. Diabetes Res 7ac. 2009;86(2):14. 45. doi:10.1016/j.diabres.2009.08.013
- ite MF. The insulin signalling system and the IRS proteins. :40(2):S2-S17. abetologia. 19
- Bakry M, Hashim R, Mustafa N, Wan Ngah WZ. 13.1 ri HZ, Makmo visation of ycaemic control during episodes of severe/acute in patients with type 2 diabetes mellitus. Int J Clin Warm. 2012;34(6):863-870. doi:10.1007/s11096-012-9682-7
- A, Exercise HM. GLUT4, and skeletal muscle glucose uptake. Physiol Rev. 2013;93:993–1017. doi:10.1152/physrev.00038.2012
- 15. Chang YJ, Pownall S, Jensen TE, et al. The Rho-guanine nucleotide exchange factor PDZ-RhoGEF governs susceptibility to diet-induced obesity and type 2 diabetes. eLife. 2015;4:e06011. doi:10.7554/ eLife.06416
- 16. Audouze K, Brunak S, Grandjean P. A computational approach to chemical etiologies of diabetes. Sci Rep. 2013;3:2712. doi:10.1038/srep02712
- 17. Ullrich S. IGF-1 and Insulin-Receptor Signalling in Insulin-Secreting Cells: From Function to Survival. Islets of Langerhans. Islets of langerhans: Springer; 2015:659-685.
- 18. Herder C, Haastert B, Müller-Scholze S, et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes. 2005;54(suppl 2):S11-S17.
- 19. Baggiolini M. Chemokines in pathology and medicine. J Intern Med. 2001;250(2):91-104.
- 20. Ahluwalia TS, Khullar M, Ahuja\ M, et al. Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One. 2009;4(4):e5168. doi:10.1371/journal.pone.0005168
- 21. Abbas A, Lichtman A, Pillai S. Cellular and Molecular Immunology: With Student Consult Online Access. Islets of langerhans: Elsevier Health Sciences: 2014.
- 22. McDermott DH, Zimmerman PA, Guignard F, et al. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet. 1998;352 (9131):866-870. doi:10.1016/S0140-6736(98)04158-0
- 23. Passam AM, Zafiropoulos A, Miyakis S, et al. CCR2-64I and CXCL12 3' A alleles confer a favorable prognosis to AIDS patients undergoing HAART therapy. J Clin Virol. 2005;34(4):302-309. doi:10.1016/j.jcv.2004.05.021

Dovepress Golsheh and Keshavarzi

- Dytfeld J, Bogdański P, Pupek-Musialik D, Jagodziński P, Bryl W, Kujawa A. Expression of chemokine receptor CCR5 in patients with type 2 diabetes. *olskie Towarzystwo Lekarskie*. 2006;20 (116):195–198.
- 25. Yousef AA, Eg B, Abd Allah W, et al. IRS1 genetic polymorphism (r.2963G>A) in type 2 diabetes mellitus patients associated with insulin resistance. *Appl Clin Genet*. 2018;11:99–106.



Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion

and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal and the submit your manuscript here. The submit your manuscript here is not your manuscript here is not your manuscript here. The submit your manuscript here is not your manuscript here is not your manuscript here. The submit your manuscript here is not your manuscript here is not your manuscript here. The submit your manuscript here is not your manuscrip